Clinical Trials Arena on MSN6m
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Managed Healthcare Executive3d
New ATS Guidelines Highlight Benefits of Pulmonary Rehabilitation
Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...
The Manila Times15h
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...
Researchers uncover the source of cells that contribute to pulmonary fibrosis
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
pharmaphorum14h
Pliant slumps on decision to pause lung disease drug trial
Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF) after seeing a ...
Using genetics to identify individuals with undiagnosed chronic obstructive pulmonary disease
In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples that can be obtained from a cheek swab or blood test, they can improve identification of people ...
Peninsula biotech sheds 60% of its value as it pauses key clinical trial
A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...
Healio3d
Smoking before age 15 years raises COPD risk in adulthood regardless of smoking factors
The adjusted risk for COPD was elevated among adults who identified as regular cigarette smokers before age 15 years, ...
Thorax2d
Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Physician's Weekly5d
Microbial Dynamics and Immune Response to NTHi in COPD
The following is a summary of “NTHi killing activity is reduced in COPD patients and is associated with a differential ...
Science Daily3d
Lung Disease News
Feb. 6, 2025 — Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life ...